Summary (tl;dr)

Moderna's stock surged dramatically after its personalized mRNA cancer vaccine for melanoma, developed with Merck, achieved positive results in a Phase 3 clinical trial, significantly reducing cancer recurrence and spread.

Essential Background

Messenger RNA (mRNA) technology gained prominence during the COVID-19 pandemic for its use in rapidly developing vaccines. For years, researchers have explored applying this technology to cancer treatment, aiming to train the immune system to recognize and attack cancer cells. Prior to this, cancer vaccines had largely faced challenges, often due to focusing on a single antigen or mutated protein. Moderna and Merck have been collaborating on a personalized mRNA cancer vaccine, intismeran (also known as mRNA-4157 or V940), combined with Merck's existing immunotherapy drug, Keytruda, for several years.

The Full Story

Moderna's stock more than doubled on Wednesday after the company, in partnership with Merck, announced successful Phase 3 trial results for their experimental mRNA cancer vaccine to treat melanoma, a deadly form of skin cancer. The personalized vaccine, intismeran, when combined with Merck's Keytruda, demonstrated statistically significant and clinically meaningful improvements by preventing melanoma from returning or spreading in high-risk patients who had undergone surgery to remove their tumors. This marks the first positive late-stage trial result for an mRNA cancer vaccine and is considered a "landmark moment" for adjuvant melanoma treatment and the broader field of cancer research. The trial involved 1,137 patients and showed no new safety signals. The companies plan to present the detailed, unpublished data at an upcoming international medical meeting and will engage with regulatory authorities to seek approval, with potential commercial approval as early as 2027.

Why It Matters

This breakthrough is significant because it provides strong evidence that mRNA technology, beyond infectious diseases, can successfully be applied to cancer treatment, potentially establishing a new treatment paradigm for melanoma and other cancers. The success offers a crucial new market for Moderna, whose stock had seen declines after its COVID-19 vaccine highs, and for Merck, as it faces patent losses for its top-selling drug Keytruda. Analysts are projecting billions of dollars in sales from the vaccine, and the positive results have led to a substantial increase in Moderna's and Merck's stock prices, reflecting investor confidence in the future of personalized mRNA cancer therapies. The potential for an approved mRNA-based cancer treatment could revolutionize how various cancers are addressed, offering new hope for patients and opening avenues for further research in lung, kidney, and bladder cancers where the treatment is also being studied.

Geographic Location

• United States (Companies Moderna and Merck headquartered, and where regulatory submissions will be made to the FDA)
• Sydney, New South Wales, Australia (Professor Georgina Long, principal investigator of the study, is from the University of Sydney)